Marshall Fordyce says Vera’s 428-patient phase 3 trial had placebo volunteers losing 5–10% of kidney function yearly. Vera persuaded FDA to analyze early, showed Trutacna helped, and switched every placebo volunteer to the drug rather than waiting for more decline. That makes patient-centricity a trial-access and accountability mechanism.
Fordyce says he attends the IgA nephropathy Foundation’s annual meeting and is the only biotech CEO who shows up to listen. Patients ask how they will get access to new medicines. He calls these exchanges sometimes awkward but argues companies should face patients and hold the business accountable.
Fordyce says Vera’s patient focus started before trials by choosing autoimmune disease and a mechanism aimed at inadequate standard of care. He points to steroid side effects—acute and chronic—as a real patient problem. He argues listening to patients reveals these harms and should shape target selection, not just marketing.
Fordyce warns against cool molecule cartoons plus money and hope. He frames the problem as medical and the solution as scientific, requiring evidence across disease biology, molecule, PK, therapeutic window, and data from dish to animals to volunteers to patients. That disciplined translation reduces risk before expensive trials.
Fordyce says he has no MBA but knows business is people and money. He states plainly that 'no cash, no company,' and because biotech mostly raises through equity, CEOs must be disciplined about stock price and financing. He sees that as a core CEO job alongside organizing people and time around translation.
Fordyce says in biotech a competitor’s good data is ultimately good news for patients and for your company. He describes the industry as working as one team, so a rival’s positive trial can validate the approach and benefit patients rather than only threatening market share.
